Gyre Therapeutics appoints David M. Epstein, Ph.D. to Board of Directors

GYRE THERAPEUTICS, INC.

David Epstein appointed as Class II director effective Aug 6, 2024; serves on Audit and Compensation Committees.
Epstein co-founded Black Diamond Therapeutics (BDTX) and PairX Bio; former CSO of OSI Pharmaceuticals.
Rodney Nussbaum appointed as Chair of Audit Committee on same date.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Epstein

Class II director

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2024-08-06
Filed: August 8, 2024, 7:59 PM ET

the Board of Directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”) appointed David Epstein, Ph.D. as a Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Epstein was appointed as Class II director at GYRE THERAPEUTICS, INC..

Action: appointed
Role: Class II director

Exact text from the filing

the Board of Directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”) appointed David Epstein, Ph.D. as a Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-036404

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.